Tislelizumab combined with Lenvatinib
iDUCONVER-001
Unknown small_molecule active
Quick answer
Tislelizumab combined with Lenvatinib for Initially Unresectable Hepatocellular Carcinoma is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Initially Unresectable Hepatocellular Carcinoma
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active